E-Articles - Finance

Taking a bit of a different spin in this article, I would like to give my insight on the IPO market. Ironically being one

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

of the main areas investment banks deal with, it should be to no surprise that investment banks typically have the best re

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

urn of any IPO put into the public market. While of course there will always be some exceptions, buying a few of these new

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

ly released stocks will almost guarantee a higher return on investment for your portfolio.

Looking at specific stocks in

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

eneral, all indications point to the sentiment that investment banks present an excellent opportunity for future capital g

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ins. For example a few years ago Goldman Sachs (GS) put an IPO in the market. Currently the stock is trading almost 1300%

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

than initially presented almost seven years ago. Typically it takes decades for a stock to reach such appreciation. Howeve

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

, with the continued trend in the investment banking community, such a percentage gain is not uncommon to smart investors.

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

While you may argue that Goldman Sachs was a well respected company before becoming public, there are many more obscure

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ompanies which have had just of great of success regardless of how recognizable the name was. Calamos Asset Management Inc

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

(CLMS) had an increase of nearly 25% in two years, Black Rock Inc. (BLK) grew nearly 1150% in five years, and Greenhill &

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

Co Inc (GHL) gained nearly 50% in less than three years. In fact out of the 32 random companies I assessed, only four or

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

2% of these companies which have been in the market for more than one year have posted capital losses and only marginal on

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

es relative to other IPOs. Furthermore, including all the IPOs in the market regardless of file date, only seven out of th

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

32 have seen any kind of capital loss regardless of any kind of fundamental or technical analysis. While as an investor y

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

u many argue that the risk is too high during infancy, by purchasing shares in four to seven of these companies, there is

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

almost a guarantee you will earn a large portion of capital gains.

Therefore, while many professionals may argue against

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

uying an IPO so quickly, remember that investment banks are the companies that underwrite IPOs in the first place and have

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

a fair say on what the price of the stock should be. While such a situation may be criticized as unfair, the opportunity

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

o win big with investment banks is highly apparent, and you as an investor should take every advantage with these fortunes

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-article.org.ua/article/103041/e-article-IPO-Update-is-Investment-Banking-the-Best-Industry-to-Invest.html">IPO Update: is Investment Banking the Best Industry to Invest?</a>

BB link (for phorums):
[url=http://www.e-article.org.ua/article/103041/e-article-IPO-Update-is-Investment-Banking-the-Best-Industry-to-Invest.html]IPO Update: is Investment Banking the Best Industry to Invest?[/url]

Without this one important element it won’t matter much how great your copy or you offer is, because few will ever read it.

Many events may drive you to bankruptcy. Actually, except in certain situations, bankruptcy is nothing but the result of a buildup of unfortunate financial decision and unexpected events. Nevertheless, there are ways to prevent it and to keep debt at a reasonable level in order to maintain a healthy financial situation.

Debt collectors are usually quite dedicated to their job but there are ways you can fight back. Find out how you can get the debt collectors to stop harassing you.

Tags

Links

E-Articles - IPO Update: is Investment Banking the Best Industry to Invest?

Related Articles: